Application of Lavermit in preparing medicine for tetanic rachitis

A technology for ankylosing spondylitis and leflunomide, which is used in drug combinations, allergic diseases, active ingredients of heterocyclic compounds, etc., can solve problems such as adverse consequences, inability to prevent disease progression, and large toxic and side effects

Inactive Publication Date: 2002-02-27
CINKATE PHARMA INTERMEDIATES
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The treatment of ankylosing spondylitis mainly includes two types of drugs, non-steroidal anti-inflammatory drugs and disease-modifying drugs. The former can only relieve pain but cannot prevent the progress of the disease, while the current disease-modifying drugs are all transplanted from drugs for treating other diseases. After using it, although it has a certain curative effect, it has relatively large toxic and side effects, and long-term use will cause many adverse consequences

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Patient, male, 38 years old, developed low back pain in March 1998, located at the sacroiliac joint, the pain gradually increased, and affected the waist movement, making the waist backward, lateral bending, rotation, etc. restricted. Then there was back pain and ankylosing spondylitis, sulfasalazine (SASP) 1.0g, 3 times / d, methotrexate (MTX) 15mg / week, and Fenbid and other non-steroidal anti-inflammatory drugs were given at the same time After treatment, the patient felt that his condition had not improved significantly, and he could not take care of himself in daily life; the pain in the lumbosacral region was aggravated, and the movements of the waist such as bending forward, backward, side bending, and turning were all limited.

[0018] In October 2000, he switched to leflunomide (trade name: Arova), stopped using sulfasalazine and MTX, and gave the initial dose of 50 mg / day, which was the loading dose for the first three days, and then maintained 20 mg / day...

Embodiment 2

[0019] Embodiment 2 Patient, male, 31 years old, was diagnosed as ankylosing spondylitis because of low back and leg pain for 4 years, SASP treatment for 1 year, plus MTX treatment for more than 7 months was ineffective, and continued use of NSAID (non-steroidal anti-inflammatory drug) and Intermittent use of glucocorticoids to relieve symptoms. In February 2001, I started to use Aruva 20mg / day, and stopped using NSAID and glucocorticoids after 6 weeks. The patient’s condition improved, and now I only use Aruva 20mg / day to maintain, and the condition is still stable. See Table 1 for details.

[0020] Table I

[0021] Comparison of changes in some clinical and laboratory indicators of patients before and after treatment with Aruva, treatment pain, morning stiffness, life Schober "4" sign refers to ground distance ESR (erythrocyte sedimentation rate) CRP (C-reactive protein) before and after treatment time self-care test is heavier 3 Hour difference 2cm ++...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an application of lyfluomite in preparation of medicine for curing ankylosing spondylitis. The lyfluomite can utilize its action of inhibiting the hyperlasia of fibrolast to reduce hyperplasia of fibrous tissue between joint and bone trabecula. Besides, it also can inhibit the hyperplasia of activated lymphocytes and conversion of B-lymphocyte into plasmocyte, and can reduce infiltration of lymphocyte and plasmocyte in articular synovium of ankylosing spondylitis. The therapeutic effect is reliable, and its toxic side effect is less, so it is an effective medicine for curing ankylosing spondylitis.

Description

[0001] Field [0002] The present invention relates to the application of leflunomide, in particular to the application of leflunomide in the preparation of medicine for treating ankylosing spondylitis. technical background [0003] Ankylosing spondylitis is a chronic, progressive autoimmune disease that mainly involves the sacroiliac joints, spine, spinal bone and soft tissue, and extremity joints. and inflammation and hyperplasia of the joint synovium of the extremities. Primary disease is more common in young men, and its age of onset varies from 4-90 years old, but it is more common in 15-20 years old, and the prevalence rate is about 0.3%. Patients with advanced ankylosing spondylitis have obvious deformities and dysfunctions, such as scoliosis, kyphosis, severe compression of the cervical spine, hip joint deformity, fixation, necrosis, and heel spurs, which are important causes of disability in the population. [0004] The pathogenesis of ankylosing spondylitis is main...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/42A61P19/00A61P37/02
Inventor 肖飞
Owner CINKATE PHARMA INTERMEDIATES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap